PMID- 28832484
DCOM- 20170908
LR  - 20180714
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Linking)
VI  - 130
IP  - 3
DP  - 2017 Sep
TI  - Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome.
PG  - e110-e126
LID - 10.1097/AOG.0000000000002296 [doi]
AB  - Hereditary breast and ovarian cancer syndrome is an inherited
      cancer-susceptibility syndrome characterized by multiple family members with
      breast cancer, ovarian cancer, or both. Based on the contemporary understanding
      of the origins and management of ovarian cancer and for simplicity in this
      document, ovarian cancer also refers to fallopian tube cancer and primary
      peritoneal cancer. Clinical genetic testing for gene mutations allows more
      precise identification of those women who are at an increased risk of inherited
      breast cancer and ovarian cancer. For these individuals, screening and prevention
      strategies can be instituted to reduce their risks. Obstetrician-gynecologists
      play an important role in the identification and management of women with
      hereditary breast and ovarian cancer syndrome. If an obstetrician-gynecologist or
      other gynecologic care provider does not have the necessary knowledge or
      expertise in cancer genetics to counsel a patient appropriately, referral to a
      genetic counselor, gynecologic or medical oncologist, or other genetics
      specialist should be considered (1). More genes are being discovered that impart 
      varying risks of breast cancer, ovarian cancer, and other types of cancer, and
      new technologies are being developed for genetic testing. This Practice Bulletin 
      focuses on the primary genetic mutations associated with hereditary breast and
      ovarian cancer syndrome, BRCA1 and BRCA2, but also will briefly discuss some of
      the other genes that have been implicated.
CN  - Committee on Practice Bulletins-Gynecology, Committee on Genetics, Society of
      Gynecologic Oncology
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
SB  - IM
MH  - Breast Neoplasms/genetics/*therapy
MH  - Female
MH  - Genetic Counseling
MH  - Genetic Predisposition to Disease
MH  - Genetic Testing
MH  - Humans
MH  - Neoplastic Syndromes, Hereditary/genetics/*therapy
MH  - Ovarian Neoplasms/genetics/*therapy
MH  - Societies, Medical
MH  - United States
IR  - Modesitt SC
FIR - Modesitt, Susan C
IR  - Lu K
FIR - Lu, Karen
IR  - Chen L
FIR - Chen, Lee-may
IR  - Powell CB
FIR - Powell, C. Bethan
EDAT- 2017/08/24 06:00
MHDA- 2017/09/09 06:00
CRDT- 2017/08/24 06:00
PHST- 2017/08/24 06:00 [entrez]
PHST- 2017/08/24 06:00 [pubmed]
PHST- 2017/09/09 06:00 [medline]
AID - 10.1097/AOG.0000000000002296 [doi]
AID - 00006250-201709000-00044 [pii]
PST - ppublish
SO  - Obstet Gynecol. 2017 Sep;130(3):e110-e126. doi: 10.1097/AOG.0000000000002296.